Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.45 |
| ▸ | SQLE | Q14534 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2456513 | 1.00 | KMT2A (0.50) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL28241054 | 0.91 | — | — | |
| SCHEMBL11733396 | 0.87 | SQLE (0.47) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11733389 | 0.87 | SQLE (0.47) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11702142 | 0.86 | KMT2A (0.50) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11702149 | 0.86 | KMT2A (0.50) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11549688 | 0.86 | KMT2A (0.50) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11549692 | 0.86 | KMT2A (0.50) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL1586840 | 0.84 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11844736 | 0.84 | KMT2A (0.73) | KMT2AMAPTMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017596-B2 | Phosphonates useful as modulators of T-γ-9-δ-2 activity | INNATE PHARMA, S.A. (FR) | 2011-09-13 | — | — | US | disclosed |
| US-20100204184-A1 | Phosphonates useful as modulators of T-gamma-9-delta-2 activity | LABORATOIRES MAYOLY SPINDLER (FR) | 2010-08-12 | — | — | US | disclosed |
| US-20060241087-A1 | Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity | MONTERO JEAN-LOUIS | 2006-10-26 | — | — | US | disclosed |
| EP-1453840-A1 | PHOSPHONATES USEFUL AS MODULATORS OF T-GAMMA-9-DELTA-2 LYMPHOCYTE ACTIVITY | Laboratoire Mayoly Spindler (FR) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003050128-A1 | PHOSPHONATES USEFUL AS MODULATORS OF T $G(G)9$G(D)2 LYMPHOCYTE ACTIVITY | LABORATOIRE MAYOLY SPINDLER (FR) | 2003-06-19 | — | — | WO | disclosed |
| US-4011335-A | INSECTICIDES, HORMONE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204184-A1 | Phosphonates useful as modulators of T-gamma-9-delta-2 activity | CD4, PRKCD, PRKCZ | KMT2A 3758/4885MAPT 3165/4885MEN1 4335/4885 |
| US-20060241087-A1 | Phosphonates useful as modulators of t $g(g)9$g(d)2 lymphocyte activity | CD4, GNG2, PLCG2 | KMT2A 3312/4885MAPT 3776/4885MEN1 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.